Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015

JAMA Internal Medicine- United States

doi 10.1001/jamainternmed.2017.8016

Full Text

Abstract

Available in

Date

Authors

Publisher

American Medical Association (AMA)

Related search

The Concept Of: Generic Drugs and Patented Drugs vs. Brand Name Drugs and Non-Proprietary (Generic) Name Drugs

Frontiers in Pharmacology
Pharmacology
2013English

Pharmacy Benefit Managers

English

Pharmacy Benefit Managers and Unique Customer Segments: Large Employers

Journal of Managed Care Pharmacy
2000English

Potential Savings From Greater Use of $4 Generic Drugs

Archives of Internal Medicine
2011English

Brand Name or Generic Drugs: A National Survey of Patient Perception and Preferences

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Brand-Name Versus Generic: The Authors Respond

Health Affairs
MedicineHealth Policy
2007English

Generic Scrip Share and the Price of Brand-Name Drugs: The Role of the Consumer

2005English

Consumer Price Differentials Between Generic and Brand Name Prescriptions.

American Journal of Public Health
EnvironmentalPublic HealthOccupational Health
1974English

Generic Selection Criteria for Safety and Patient Benefit [VIII]: Comparing the Physicochemical and Pharmaceutical Properties of Brand-Name and Generic Diclofenac Sodium Tapes

Drug discoveries & therapeutics
MedicineToxicologyPharmaceuticsPharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy